nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—CA6—saliva—nicotine dependence	0.031	0.104	CbGeAlD
Nilotinib—Cardiac flutter—Varenicline—nicotine dependence	0.027	0.0537	CcSEcCtD
Nilotinib—Pleurisy—Varenicline—nicotine dependence	0.0181	0.0361	CcSEcCtD
Nilotinib—Enterocolitis—Varenicline—nicotine dependence	0.0159	0.0318	CcSEcCtD
Nilotinib—Restless legs syndrome—Varenicline—nicotine dependence	0.0155	0.0309	CcSEcCtD
Nilotinib—Musculoskeletal chest pain—Varenicline—nicotine dependence	0.0114	0.0227	CcSEcCtD
Nilotinib—Coronary artery disease—Varenicline—nicotine dependence	0.0112	0.0223	CcSEcCtD
Nilotinib—Dysphoria—Varenicline—nicotine dependence	0.0102	0.0204	CcSEcCtD
Nilotinib—CDC42BPB—cardiovascular system—nicotine dependence	0.00961	0.0323	CbGeAlD
Nilotinib—Transient ischaemic attack—Varenicline—nicotine dependence	0.00877	0.0175	CcSEcCtD
Nilotinib—Throat irritation—Varenicline—nicotine dependence	0.00877	0.0175	CcSEcCtD
Nilotinib—MAPK8—cardiovascular system—nicotine dependence	0.00869	0.0292	CbGeAlD
Nilotinib—Night sweats—Varenicline—nicotine dependence	0.0082	0.0163	CcSEcCtD
Nilotinib—Gastric ulcer—Varenicline—nicotine dependence	0.00762	0.0152	CcSEcCtD
Nilotinib—TIE1—cardiovascular system—nicotine dependence	0.00754	0.0253	CbGeAlD
Nilotinib—CDC42BPB—midbrain—nicotine dependence	0.00751	0.0252	CbGeAlD
Nilotinib—Psoriasis—Varenicline—nicotine dependence	0.00704	0.014	CcSEcCtD
Nilotinib—MAPK8—midbrain—nicotine dependence	0.00679	0.0228	CbGeAlD
Nilotinib—Cyst—Varenicline—nicotine dependence	0.00662	0.0132	CcSEcCtD
Nilotinib—Pharyngolaryngeal pain—Varenicline—nicotine dependence	0.00656	0.0131	CcSEcCtD
Nilotinib—Laryngeal pain—Varenicline—nicotine dependence	0.00649	0.0129	CcSEcCtD
Nilotinib—Haematemesis—Varenicline—nicotine dependence	0.00637	0.0127	CcSEcCtD
Nilotinib—Thrombosis—Varenicline—nicotine dependence	0.00625	0.0125	CcSEcCtD
Nilotinib—Hyperlipidaemia—Varenicline—nicotine dependence	0.00614	0.0122	CcSEcCtD
Nilotinib—Menorrhagia—Varenicline—nicotine dependence	0.00598	0.0119	CcSEcCtD
Nilotinib—CA3—cardiovascular system—nicotine dependence	0.00592	0.0199	CbGeAlD
Nilotinib—BRAF—midbrain—nicotine dependence	0.00564	0.019	CbGeAlD
Nilotinib—Gingivitis—Varenicline—nicotine dependence	0.00564	0.0112	CcSEcCtD
Nilotinib—MAPK14—cardiovascular system—nicotine dependence	0.00552	0.0186	CbGeAlD
Nilotinib—FGR—cardiovascular system—nicotine dependence	0.0055	0.0185	CbGeAlD
Nilotinib—Dysphonia—Varenicline—nicotine dependence	0.00538	0.0107	CcSEcCtD
Nilotinib—Endocrine disorder—Varenicline—nicotine dependence	0.00534	0.0106	CcSEcCtD
Nilotinib—EPHB2—brain—nicotine dependence	0.00534	0.0179	CbGeAlD
Nilotinib—EPHB4—cardiovascular system—nicotine dependence	0.00523	0.0176	CbGeAlD
Nilotinib—Eye irritation—Varenicline—nicotine dependence	0.00518	0.0103	CcSEcCtD
Nilotinib—HCK—midbrain—nicotine dependence	0.00515	0.0173	CbGeAlD
Nilotinib—EPHA2—cardiovascular system—nicotine dependence	0.00514	0.0173	CbGeAlD
Nilotinib—EPHA8—brain—nicotine dependence	0.00512	0.0172	CbGeAlD
Nilotinib—Disturbance in attention—Varenicline—nicotine dependence	0.00511	0.0102	CcSEcCtD
Nilotinib—CA7—midbrain—nicotine dependence	0.00504	0.0169	CbGeAlD
Nilotinib—TEK—cardiovascular system—nicotine dependence	0.00501	0.0168	CbGeAlD
Nilotinib—Chest discomfort—Varenicline—nicotine dependence	0.005	0.00996	CcSEcCtD
Nilotinib—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.0049	0.00976	CcSEcCtD
Nilotinib—Ventricular extrasystoles—Varenicline—nicotine dependence	0.0049	0.00976	CcSEcCtD
Nilotinib—Nocturia—Varenicline—nicotine dependence	0.00477	0.0095	CcSEcCtD
Nilotinib—MAPK11—brain—nicotine dependence	0.00476	0.016	CbGeAlD
Nilotinib—CDC42BPB—brain—nicotine dependence	0.00472	0.0159	CbGeAlD
Nilotinib—Leukocytosis—Varenicline—nicotine dependence	0.00471	0.00938	CcSEcCtD
Nilotinib—PDGFRA—cardiovascular system—nicotine dependence	0.00454	0.0153	CbGeAlD
Nilotinib—Musculoskeletal pain—Varenicline—nicotine dependence	0.00448	0.00892	CcSEcCtD
Nilotinib—EPHA3—brain—nicotine dependence	0.00447	0.015	CbGeAlD
Nilotinib—Blood pressure increased—Varenicline—nicotine dependence	0.00443	0.00882	CcSEcCtD
Nilotinib—Hyperkalaemia—Varenicline—nicotine dependence	0.00435	0.00866	CcSEcCtD
Nilotinib—Influenza like illness—Varenicline—nicotine dependence	0.0043	0.00856	CcSEcCtD
Nilotinib—MAPK8—brain—nicotine dependence	0.00427	0.0143	CbGeAlD
Nilotinib—EPHA6—brain—nicotine dependence	0.00427	0.0143	CbGeAlD
Nilotinib—CA14—midbrain—nicotine dependence	0.00419	0.0141	CbGeAlD
Nilotinib—Photophobia—Varenicline—nicotine dependence	0.00416	0.00828	CcSEcCtD
Nilotinib—MAP2K5—cardiovascular system—nicotine dependence	0.00409	0.0138	CbGeAlD
Nilotinib—EPHB4—midbrain—nicotine dependence	0.00409	0.0137	CbGeAlD
Nilotinib—Dry eye—Varenicline—nicotine dependence	0.00409	0.00814	CcSEcCtD
Nilotinib—Mouth ulceration—Varenicline—nicotine dependence	0.004	0.00797	CcSEcCtD
Nilotinib—CSF1R—cardiovascular system—nicotine dependence	0.004	0.0134	CbGeAlD
Nilotinib—LYN—brain—nicotine dependence	0.00394	0.0132	CbGeAlD
Nilotinib—TEK—midbrain—nicotine dependence	0.00391	0.0132	CbGeAlD
Nilotinib—MAP4K1—brain—nicotine dependence	0.00388	0.013	CbGeAlD
Nilotinib—EPHB6—midbrain—nicotine dependence	0.00374	0.0126	CbGeAlD
Nilotinib—TIE1—brain—nicotine dependence	0.0037	0.0124	CbGeAlD
Nilotinib—Diabetes mellitus—Varenicline—nicotine dependence	0.00369	0.00736	CcSEcCtD
Nilotinib—KIT—cardiovascular system—nicotine dependence	0.00363	0.0122	CbGeAlD
Nilotinib—Disorientation—Varenicline—nicotine dependence	0.00359	0.00715	CcSEcCtD
Nilotinib—Deafness—Varenicline—nicotine dependence	0.00359	0.00715	CcSEcCtD
Nilotinib—Eczema—Varenicline—nicotine dependence	0.00357	0.00712	CcSEcCtD
Nilotinib—Eye pain—Varenicline—nicotine dependence	0.00356	0.00709	CcSEcCtD
Nilotinib—BRAF—brain—nicotine dependence	0.00355	0.0119	CbGeAlD
Nilotinib—PDGFRB—cardiovascular system—nicotine dependence	0.00354	0.0119	CbGeAlD
Nilotinib—EPHB3—brain—nicotine dependence	0.00352	0.0118	CbGeAlD
Nilotinib—Increased appetite—Varenicline—nicotine dependence	0.00342	0.00681	CcSEcCtD
Nilotinib—Amnesia—Varenicline—nicotine dependence	0.00342	0.00681	CcSEcCtD
Nilotinib—Atrial fibrillation—Varenicline—nicotine dependence	0.00339	0.00675	CcSEcCtD
Nilotinib—CA1—cardiovascular system—nicotine dependence	0.00332	0.0112	CbGeAlD
Nilotinib—Arthritis—Varenicline—nicotine dependence	0.00331	0.00659	CcSEcCtD
Nilotinib—Hypoglycaemia—Varenicline—nicotine dependence	0.00329	0.00656	CcSEcCtD
Nilotinib—Lethargy—Varenicline—nicotine dependence	0.00328	0.00653	CcSEcCtD
Nilotinib—HCK—brain—nicotine dependence	0.00323	0.0109	CbGeAlD
Nilotinib—ABL2—brain—nicotine dependence	0.00321	0.0108	CbGeAlD
Nilotinib—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.00321	0.0064	CcSEcCtD
Nilotinib—MAP2K5—midbrain—nicotine dependence	0.0032	0.0107	CbGeAlD
Nilotinib—CA7—brain—nicotine dependence	0.00316	0.0106	CbGeAlD
Nilotinib—Migraine—Varenicline—nicotine dependence	0.00316	0.0063	CcSEcCtD
Nilotinib—ABL1—cardiovascular system—nicotine dependence	0.00316	0.0106	CbGeAlD
Nilotinib—CSF1R—midbrain—nicotine dependence	0.00312	0.0105	CbGeAlD
Nilotinib—Dry skin—Varenicline—nicotine dependence	0.00294	0.00587	CcSEcCtD
Nilotinib—EPHA4—brain—nicotine dependence	0.00294	0.00988	CbGeAlD
Nilotinib—Abdominal pain upper—Varenicline—nicotine dependence	0.00293	0.00585	CcSEcCtD
Nilotinib—Hypokalaemia—Varenicline—nicotine dependence	0.00292	0.00582	CcSEcCtD
Nilotinib—Breast disorder—Varenicline—nicotine dependence	0.0029	0.00578	CcSEcCtD
Nilotinib—CA3—brain—nicotine dependence	0.0029	0.00976	CbGeAlD
Nilotinib—Nasopharyngitis—Varenicline—nicotine dependence	0.00287	0.00572	CcSEcCtD
Nilotinib—Gastritis—Varenicline—nicotine dependence	0.00284	0.00566	CcSEcCtD
Nilotinib—KIT—midbrain—nicotine dependence	0.00283	0.00952	CbGeAlD
Nilotinib—Abdominal distension—Varenicline—nicotine dependence	0.0028	0.00557	CcSEcCtD
Nilotinib—PDGFRB—midbrain—nicotine dependence	0.00277	0.0093	CbGeAlD
Nilotinib—MAPK14—brain—nicotine dependence	0.00271	0.00911	CbGeAlD
Nilotinib—Angina pectoris—Varenicline—nicotine dependence	0.0027	0.00539	CcSEcCtD
Nilotinib—FGR—brain—nicotine dependence	0.0027	0.00907	CbGeAlD
Nilotinib—Bronchitis—Varenicline—nicotine dependence	0.00267	0.00532	CcSEcCtD
Nilotinib—Abdominal discomfort—Varenicline—nicotine dependence	0.00266	0.0053	CcSEcCtD
Nilotinib—CA14—brain—nicotine dependence	0.00264	0.00886	CbGeAlD
Nilotinib—CA4—cardiovascular system—nicotine dependence	0.00259	0.00872	CbGeAlD
Nilotinib—EPHB4—brain—nicotine dependence	0.00257	0.00863	CbGeAlD
Nilotinib—Pollakiuria—Varenicline—nicotine dependence	0.00256	0.00511	CcSEcCtD
Nilotinib—Erectile dysfunction—Varenicline—nicotine dependence	0.00256	0.00509	CcSEcCtD
Nilotinib—Photosensitivity reaction—Varenicline—nicotine dependence	0.00253	0.00505	CcSEcCtD
Nilotinib—Weight increased—Varenicline—nicotine dependence	0.00253	0.00503	CcSEcCtD
Nilotinib—EPHA2—brain—nicotine dependence	0.00252	0.00847	CbGeAlD
Nilotinib—Hyperglycaemia—Varenicline—nicotine dependence	0.0025	0.00499	CcSEcCtD
Nilotinib—Infestation—Varenicline—nicotine dependence	0.00248	0.00493	CcSEcCtD
Nilotinib—Infestation NOS—Varenicline—nicotine dependence	0.00248	0.00493	CcSEcCtD
Nilotinib—ABL1—midbrain—nicotine dependence	0.00247	0.00829	CbGeAlD
Nilotinib—TEK—brain—nicotine dependence	0.00246	0.00826	CbGeAlD
Nilotinib—Acute coronary syndrome—Varenicline—nicotine dependence	0.00244	0.00486	CcSEcCtD
Nilotinib—Myocardial infarction—Varenicline—nicotine dependence	0.00243	0.00483	CcSEcCtD
Nilotinib—Stomatitis—Varenicline—nicotine dependence	0.00241	0.00481	CcSEcCtD
Nilotinib—Conjunctivitis—Varenicline—nicotine dependence	0.00241	0.00479	CcSEcCtD
Nilotinib—EPHB6—brain—nicotine dependence	0.00235	0.0079	CbGeAlD
Nilotinib—Hepatobiliary disease—Varenicline—nicotine dependence	0.00234	0.00466	CcSEcCtD
Nilotinib—Epistaxis—Varenicline—nicotine dependence	0.00234	0.00465	CcSEcCtD
Nilotinib—Bradycardia—Varenicline—nicotine dependence	0.00226	0.00451	CcSEcCtD
Nilotinib—PDGFRA—brain—nicotine dependence	0.00223	0.00749	CbGeAlD
Nilotinib—Hypoaesthesia—Varenicline—nicotine dependence	0.00221	0.00441	CcSEcCtD
Nilotinib—Urinary tract disorder—Varenicline—nicotine dependence	0.00219	0.00437	CcSEcCtD
Nilotinib—Oedema peripheral—Varenicline—nicotine dependence	0.00219	0.00436	CcSEcCtD
Nilotinib—Connective tissue disorder—Varenicline—nicotine dependence	0.00218	0.00435	CcSEcCtD
Nilotinib—Urethral disorder—Varenicline—nicotine dependence	0.00218	0.00434	CcSEcCtD
Nilotinib—CA2—cardiovascular system—nicotine dependence	0.00215	0.00723	CbGeAlD
Nilotinib—Visual impairment—Varenicline—nicotine dependence	0.00214	0.00427	CcSEcCtD
Nilotinib—Erythema multiforme—Varenicline—nicotine dependence	0.0021	0.00419	CcSEcCtD
Nilotinib—Eye disorder—Varenicline—nicotine dependence	0.00208	0.00414	CcSEcCtD
Nilotinib—Tinnitus—Varenicline—nicotine dependence	0.00207	0.00413	CcSEcCtD
Nilotinib—Cardiac disorder—Varenicline—nicotine dependence	0.00206	0.00411	CcSEcCtD
Nilotinib—CA12—brain—nicotine dependence	0.00206	0.00691	CbGeAlD
Nilotinib—CA4—midbrain—nicotine dependence	0.00203	0.00681	CbGeAlD
Nilotinib—Angiopathy—Varenicline—nicotine dependence	0.00202	0.00402	CcSEcCtD
Nilotinib—MAP2K5—brain—nicotine dependence	0.00201	0.00675	CbGeAlD
Nilotinib—Immune system disorder—Varenicline—nicotine dependence	0.00201	0.004	CcSEcCtD
Nilotinib—Mediastinal disorder—Varenicline—nicotine dependence	0.002	0.00399	CcSEcCtD
Nilotinib—Chills—Varenicline—nicotine dependence	0.00199	0.00397	CcSEcCtD
Nilotinib—Arrhythmia—Varenicline—nicotine dependence	0.00199	0.00396	CcSEcCtD
Nilotinib—CSF1R—brain—nicotine dependence	0.00196	0.00659	CbGeAlD
Nilotinib—Mental disorder—Varenicline—nicotine dependence	0.00195	0.00388	CcSEcCtD
Nilotinib—Malnutrition—Varenicline—nicotine dependence	0.00193	0.00385	CcSEcCtD
Nilotinib—Erythema—Varenicline—nicotine dependence	0.00193	0.00385	CcSEcCtD
Nilotinib—Flatulence—Varenicline—nicotine dependence	0.00191	0.0038	CcSEcCtD
Nilotinib—Dysgeusia—Varenicline—nicotine dependence	0.00189	0.00377	CcSEcCtD
Nilotinib—Back pain—Varenicline—nicotine dependence	0.00187	0.00373	CcSEcCtD
Nilotinib—Muscle spasms—Varenicline—nicotine dependence	0.00186	0.00371	CcSEcCtD
Nilotinib—CYP2B6—cardiovascular system—nicotine dependence	0.00184	0.00618	CbGeAlD
Nilotinib—Vision blurred—Varenicline—nicotine dependence	0.00182	0.00363	CcSEcCtD
Nilotinib—CYP2C9—cardiovascular system—nicotine dependence	0.00182	0.00612	CbGeAlD
Nilotinib—Tremor—Varenicline—nicotine dependence	0.00181	0.00361	CcSEcCtD
Nilotinib—Ill-defined disorder—Varenicline—nicotine dependence	0.0018	0.00358	CcSEcCtD
Nilotinib—Anaemia—Varenicline—nicotine dependence	0.00179	0.00356	CcSEcCtD
Nilotinib—KIT—brain—nicotine dependence	0.00178	0.00599	CbGeAlD
Nilotinib—MAPK8—ErbB1 downstream signaling—WASF2—nicotine dependence	0.00175	0.00872	CbGpPWpGaD
Nilotinib—Malaise—Varenicline—nicotine dependence	0.00174	0.00348	CcSEcCtD
Nilotinib—PDGFRB—brain—nicotine dependence	0.00174	0.00585	CbGeAlD
Nilotinib—Vertigo—Varenicline—nicotine dependence	0.00174	0.00346	CcSEcCtD
Nilotinib—Syncope—Varenicline—nicotine dependence	0.00173	0.00346	CcSEcCtD
Nilotinib—Palpitations—Varenicline—nicotine dependence	0.00171	0.00341	CcSEcCtD
Nilotinib—MAPK8—TCR Signaling Pathway—OPRM1—nicotine dependence	0.00171	0.00852	CbGpPWpGaD
Nilotinib—ABL1—Regulation of actin dynamics for phagocytic cup formation—WASF2—nicotine dependence	0.0017	0.00849	CbGpPWpGaD
Nilotinib—Loss of consciousness—Varenicline—nicotine dependence	0.0017	0.00339	CcSEcCtD
Nilotinib—MAPK14—RAC1 signaling pathway—WASF2—nicotine dependence	0.00169	0.00844	CbGpPWpGaD
Nilotinib—Cough—Varenicline—nicotine dependence	0.00169	0.00336	CcSEcCtD
Nilotinib—CA2—midbrain—nicotine dependence	0.00168	0.00565	CbGeAlD
Nilotinib—HCK—PDGFR-beta signaling pathway—WASF2—nicotine dependence	0.00168	0.00837	CbGpPWpGaD
Nilotinib—BRAF—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00168	0.00836	CbGpPWpGaD
Nilotinib—Hypertension—Varenicline—nicotine dependence	0.00167	0.00333	CcSEcCtD
Nilotinib—MAP2K5—ErbB1 downstream signaling—WASF2—nicotine dependence	0.00166	0.00829	CbGpPWpGaD
Nilotinib—Myalgia—Varenicline—nicotine dependence	0.00165	0.00328	CcSEcCtD
Nilotinib—Arthralgia—Varenicline—nicotine dependence	0.00165	0.00328	CcSEcCtD
Nilotinib—Chest pain—Varenicline—nicotine dependence	0.00165	0.00328	CcSEcCtD
Nilotinib—Anxiety—Varenicline—nicotine dependence	0.00164	0.00327	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00164	0.00326	CcSEcCtD
Nilotinib—ABL1—Regulation of actin dynamics for phagocytic cup formation—WASF1—nicotine dependence	0.00163	0.00814	CbGpPWpGaD
Nilotinib—CA1—brain—nicotine dependence	0.00163	0.00547	CbGeAlD
Nilotinib—Discomfort—Varenicline—nicotine dependence	0.00163	0.00324	CcSEcCtD
Nilotinib—MAPK14—RAC1 signaling pathway—WASF1—nicotine dependence	0.00162	0.00809	CbGpPWpGaD
Nilotinib—Dry mouth—Varenicline—nicotine dependence	0.00161	0.00321	CcSEcCtD
Nilotinib—BRAF—Transmission across Chemical Synapses—CHRNB3—nicotine dependence	0.00159	0.00791	CbGpPWpGaD
Nilotinib—Oedema—Varenicline—nicotine dependence	0.00158	0.00315	CcSEcCtD
Nilotinib—Infection—Varenicline—nicotine dependence	0.00157	0.00313	CcSEcCtD
Nilotinib—ABCG2—midbrain—nicotine dependence	0.00156	0.00523	CbGeAlD
Nilotinib—Shock—Varenicline—nicotine dependence	0.00155	0.00309	CcSEcCtD
Nilotinib—ABL1—brain—nicotine dependence	0.00155	0.00521	CbGeAlD
Nilotinib—Nervous system disorder—Varenicline—nicotine dependence	0.00155	0.00308	CcSEcCtD
Nilotinib—Thrombocytopenia—Varenicline—nicotine dependence	0.00155	0.00308	CcSEcCtD
Nilotinib—Tachycardia—Varenicline—nicotine dependence	0.00154	0.00307	CcSEcCtD
Nilotinib—Skin disorder—Varenicline—nicotine dependence	0.00153	0.00306	CcSEcCtD
Nilotinib—Hyperhidrosis—Varenicline—nicotine dependence	0.00153	0.00304	CcSEcCtD
Nilotinib—MAPK8—PDGFR-beta signaling pathway—WASF2—nicotine dependence	0.00152	0.00759	CbGpPWpGaD
Nilotinib—BLK—PDGFR-beta signaling pathway—WASF2—nicotine dependence	0.00152	0.00759	CbGpPWpGaD
Nilotinib—FGR—PDGFR-beta signaling pathway—WASF2—nicotine dependence	0.00152	0.00756	CbGpPWpGaD
Nilotinib—Anorexia—Varenicline—nicotine dependence	0.00151	0.003	CcSEcCtD
Nilotinib—BRAF—Transmission across Chemical Synapses—CHRNA6—nicotine dependence	0.0015	0.0075	CbGpPWpGaD
Nilotinib—Hypotension—Varenicline—nicotine dependence	0.00148	0.00294	CcSEcCtD
Nilotinib—BRAF—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA4—nicotine dependence	0.00145	0.00722	CbGpPWpGaD
Nilotinib—PDGFRA—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00144	0.0072	CbGpPWpGaD
Nilotinib—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00144	0.00287	CcSEcCtD
Nilotinib—Insomnia—Varenicline—nicotine dependence	0.00143	0.00285	CcSEcCtD
Nilotinib—Dyspnoea—Varenicline—nicotine dependence	0.00141	0.0028	CcSEcCtD
Nilotinib—Dyspepsia—Varenicline—nicotine dependence	0.00139	0.00277	CcSEcCtD
Nilotinib—BRAF—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB4—nicotine dependence	0.00139	0.00692	CbGpPWpGaD
Nilotinib—BRAF—ErbB1 downstream signaling—WASF2—nicotine dependence	0.00138	0.00688	CbGpPWpGaD
Nilotinib—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00138	0.00688	CbGpPWpGaD
Nilotinib—MAPK11—VEGFA-VEGFR2 Pathway—WASF2—nicotine dependence	0.00137	0.00684	CbGpPWpGaD
Nilotinib—Decreased appetite—Varenicline—nicotine dependence	0.00137	0.00273	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00136	0.00272	CcSEcCtD
Nilotinib—Fatigue—Varenicline—nicotine dependence	0.00136	0.00271	CcSEcCtD
Nilotinib—Constipation—Varenicline—nicotine dependence	0.00135	0.00269	CcSEcCtD
Nilotinib—Pain—Varenicline—nicotine dependence	0.00135	0.00269	CcSEcCtD
Nilotinib—MAPK11—VEGFA-VEGFR2 Pathway—WASF1—nicotine dependence	0.00132	0.00656	CbGpPWpGaD
Nilotinib—MAPK14—IL4-mediated signaling events—OPRM1—nicotine dependence	0.00131	0.00652	CbGpPWpGaD
Nilotinib—PDGFRB—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.0013	0.00649	CbGpPWpGaD
Nilotinib—Feeling abnormal—Varenicline—nicotine dependence	0.0013	0.00259	CcSEcCtD
Nilotinib—MAPK11—Signaling by VEGF—WASF2—nicotine dependence	0.0013	0.00646	CbGpPWpGaD
Nilotinib—LYN—Fcgamma receptor (FCGR) dependent phagocytosis—WASF2—nicotine dependence	0.00129	0.00644	CbGpPWpGaD
Nilotinib—Gastrointestinal pain—Varenicline—nicotine dependence	0.00129	0.00257	CcSEcCtD
Nilotinib—BRAF—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—nicotine dependence	0.00129	0.00643	CbGpPWpGaD
Nilotinib—ABL1—Fcgamma receptor (FCGR) dependent phagocytosis—WASF2—nicotine dependence	0.00129	0.00641	CbGpPWpGaD
Nilotinib—CA4—brain—nicotine dependence	0.00127	0.00428	CbGeAlD
Nilotinib—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00126	0.00629	CbGpPWpGaD
Nilotinib—MAPK8—Signaling by NGF—FGD1—nicotine dependence	0.00126	0.00629	CbGpPWpGaD
Nilotinib—Urticaria—Varenicline—nicotine dependence	0.00125	0.0025	CcSEcCtD
Nilotinib—Abdominal pain—Varenicline—nicotine dependence	0.00125	0.00249	CcSEcCtD
Nilotinib—Body temperature increased—Varenicline—nicotine dependence	0.00125	0.00249	CcSEcCtD
Nilotinib—CYP2B6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00124	0.0062	CbGpPWpGaD
Nilotinib—MAPK11—Signaling by VEGF—WASF1—nicotine dependence	0.00124	0.00619	CbGpPWpGaD
Nilotinib—LYN—Fcgamma receptor (FCGR) dependent phagocytosis—WASF1—nicotine dependence	0.00124	0.00617	CbGpPWpGaD
Nilotinib—ABL1—Fcgamma receptor (FCGR) dependent phagocytosis—WASF1—nicotine dependence	0.00123	0.00614	CbGpPWpGaD
Nilotinib—BRAF—Neuronal System—CHRNB3—nicotine dependence	0.00122	0.00606	CbGpPWpGaD
Nilotinib—BRAF—PDGFR-beta signaling pathway—WASF2—nicotine dependence	0.0012	0.00599	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling by NGF—FGD1—nicotine dependence	0.0012	0.00598	CbGpPWpGaD
Nilotinib—Hypersensitivity—Varenicline—nicotine dependence	0.00116	0.00232	CcSEcCtD
Nilotinib—BRAF—Neuronal System—CHRNA6—nicotine dependence	0.00115	0.00575	CbGpPWpGaD
Nilotinib—Asthenia—Varenicline—nicotine dependence	0.00113	0.00226	CcSEcCtD
Nilotinib—Pruritus—Varenicline—nicotine dependence	0.00112	0.00223	CcSEcCtD
Nilotinib—BRAF—Transmission across Chemical Synapses—GABRA4—nicotine dependence	0.00109	0.00542	CbGpPWpGaD
Nilotinib—Diarrhoea—Varenicline—nicotine dependence	0.00108	0.00215	CcSEcCtD
Nilotinib—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00107	0.00532	CbGpPWpGaD
Nilotinib—CA2—brain—nicotine dependence	0.00106	0.00355	CbGeAlD
Nilotinib—CYP2C8—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00105	0.00525	CbGpPWpGaD
Nilotinib—BRAF—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—nicotine dependence	0.00105	0.00524	CbGpPWpGaD
Nilotinib—Dizziness—Varenicline—nicotine dependence	0.00104	0.00208	CcSEcCtD
Nilotinib—BRAF—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00104	0.0052	CbGpPWpGaD
Nilotinib—BRAF—Transmission across Chemical Synapses—CHRNB4—nicotine dependence	0.00104	0.0052	CbGpPWpGaD
Nilotinib—CYP2B6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00102	0.0051	CbGpPWpGaD
Nilotinib—CYP2C8—brain—nicotine dependence	0.00101	0.00338	CbGeAlD
Nilotinib—MAPK11—Signaling by NGF—FGD1—nicotine dependence	0.001	0.00501	CbGpPWpGaD
Nilotinib—Vomiting—Varenicline—nicotine dependence	0.001	0.002	CcSEcCtD
Nilotinib—BRAF—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.001	0.00499	CbGpPWpGaD
Nilotinib—Rash—Varenicline—nicotine dependence	0.000996	0.00198	CcSEcCtD
Nilotinib—BRAF—Signaling by NGF—FGD1—nicotine dependence	0.000995	0.00496	CbGpPWpGaD
Nilotinib—Dermatitis—Varenicline—nicotine dependence	0.000995	0.00198	CcSEcCtD
Nilotinib—Headache—Varenicline—nicotine dependence	0.000989	0.00197	CcSEcCtD
Nilotinib—ABCB1—cardiovascular system—nicotine dependence	0.000982	0.0033	CbGeAlD
Nilotinib—MAPK14—VEGFA-VEGFR2 Pathway—WASF2—nicotine dependence	0.00098	0.00488	CbGpPWpGaD
Nilotinib—ABCG2—brain—nicotine dependence	0.000977	0.00329	CbGeAlD
Nilotinib—MAPK14—TCR Signaling Pathway—OPRM1—nicotine dependence	0.000971	0.00484	CbGpPWpGaD
Nilotinib—BRAF—Transmission across Chemical Synapses—CHRNA5—nicotine dependence	0.00097	0.00483	CbGpPWpGaD
Nilotinib—MAPK14—VEGFA-VEGFR2 Pathway—WASF1—nicotine dependence	0.000939	0.00468	CbGpPWpGaD
Nilotinib—Nausea—Varenicline—nicotine dependence	0.000938	0.00187	CcSEcCtD
Nilotinib—PDGFRB—PDGFR-beta signaling pathway—WASF2—nicotine dependence	0.000932	0.00465	CbGpPWpGaD
Nilotinib—UGT1A1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000926	0.00462	CbGpPWpGaD
Nilotinib—BRAF—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB2—nicotine dependence	0.000926	0.00462	CbGpPWpGaD
Nilotinib—MAPK14—Signaling by VEGF—WASF2—nicotine dependence	0.000925	0.00461	CbGpPWpGaD
Nilotinib—LYN—PDGFR-beta signaling pathway—WASF2—nicotine dependence	0.000913	0.00455	CbGpPWpGaD
Nilotinib—ABL1—PDGFR-beta signaling pathway—WASF2—nicotine dependence	0.000908	0.00453	CbGpPWpGaD
Nilotinib—KIT—Signaling by NGF—FGD1—nicotine dependence	0.000906	0.00452	CbGpPWpGaD
Nilotinib—CYP2B6—brain—nicotine dependence	0.000902	0.00303	CbGeAlD
Nilotinib—PDGFRA—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.000899	0.00448	CbGpPWpGaD
Nilotinib—MAPK14—Signaling by VEGF—WASF1—nicotine dependence	0.000887	0.00442	CbGpPWpGaD
Nilotinib—MAPK8—Circadian rythm related genes—CHRNB2—nicotine dependence	0.000878	0.00438	CbGpPWpGaD
Nilotinib—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000876	0.00437	CbGpPWpGaD
Nilotinib—UGT1A1—Biological oxidations—CYP2A7—nicotine dependence	0.000873	0.00435	CbGpPWpGaD
Nilotinib—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000869	0.00433	CbGpPWpGaD
Nilotinib—CYP2C8—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000865	0.00431	CbGpPWpGaD
Nilotinib—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000865	0.00431	CbGpPWpGaD
Nilotinib—PDGFRA—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.000862	0.0043	CbGpPWpGaD
Nilotinib—UGT1A1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000861	0.00429	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by NGF—FGD1—nicotine dependence	0.000857	0.00427	CbGpPWpGaD
Nilotinib—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000857	0.00427	CbGpPWpGaD
Nilotinib—BRAF—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA4—nicotine dependence	0.000841	0.00419	CbGpPWpGaD
Nilotinib—BRAF—Neuronal System—GABRA4—nicotine dependence	0.000834	0.00416	CbGpPWpGaD
Nilotinib—PDGFRB—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00081	0.00404	CbGpPWpGaD
Nilotinib—BRAF—Neuronal System—CHRNB4—nicotine dependence	0.000799	0.00398	CbGpPWpGaD
Nilotinib—BRAF—Transmission across Chemical Synapses—CHRNA3—nicotine dependence	0.00079	0.00394	CbGpPWpGaD
Nilotinib—PDGFRB—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.000776	0.00387	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by NGF—FGD1—nicotine dependence	0.000772	0.00385	CbGpPWpGaD
Nilotinib—ABCB1—midbrain—nicotine dependence	0.000767	0.00258	CbGeAlD
Nilotinib—LCK—PDGFR-beta signaling pathway—WASF2—nicotine dependence	0.000748	0.00373	CbGpPWpGaD
Nilotinib—BRAF—Neuronal System—CHRNA5—nicotine dependence	0.000743	0.0037	CbGpPWpGaD
Nilotinib—MAPK14—Signaling by NGF—FGD1—nicotine dependence	0.000717	0.00357	CbGpPWpGaD
Nilotinib—CA3—Metabolism—CYP2A7—nicotine dependence	0.000716	0.00357	CbGpPWpGaD
Nilotinib—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00071	0.00354	CbGpPWpGaD
Nilotinib—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000704	0.00351	CbGpPWpGaD
Nilotinib—BRAF—Transmission across Chemical Synapses—CHRNB2—nicotine dependence	0.000696	0.00347	CbGpPWpGaD
Nilotinib—CYP2D6—brain—nicotine dependence	0.00067	0.00225	CbGeAlD
Nilotinib—MAPK8—Circadian rythm related genes—DRD2—nicotine dependence	0.000649	0.00324	CbGpPWpGaD
Nilotinib—BRAF—Transmission across Chemical Synapses—CHRNA4—nicotine dependence	0.000632	0.00315	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—FGD1—nicotine dependence	0.00062	0.00309	CbGpPWpGaD
Nilotinib—BRAF—Neuronal System—CHRNA3—nicotine dependence	0.000606	0.00302	CbGpPWpGaD
Nilotinib—CYP2B6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000576	0.00287	CbGpPWpGaD
Nilotinib—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000573	0.00286	CbGpPWpGaD
Nilotinib—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000565	0.00282	CbGpPWpGaD
Nilotinib—CYP2B6—Biological oxidations—CYP2A7—nicotine dependence	0.000543	0.00271	CbGpPWpGaD
Nilotinib—CYP2B6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000535	0.00267	CbGpPWpGaD
Nilotinib—BRAF—Neuronal System—CHRNB2—nicotine dependence	0.000533	0.00266	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—WASF2—nicotine dependence	0.000494	0.00246	CbGpPWpGaD
Nilotinib—CYP2C8—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000488	0.00243	CbGpPWpGaD
Nilotinib—BRAF—Neuronal System—CHRNA4—nicotine dependence	0.000484	0.00241	CbGpPWpGaD
Nilotinib—ABCB1—brain—nicotine dependence	0.000482	0.00162	CbGeAlD
Nilotinib—HCK—Innate Immune System—WASF1—nicotine dependence	0.000474	0.00236	CbGpPWpGaD
Nilotinib—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000464	0.00232	CbGpPWpGaD
Nilotinib—CA14—Metabolism—CYP2A7—nicotine dependence	0.000461	0.0023	CbGpPWpGaD
Nilotinib—CYP2C8—Biological oxidations—CYP2A7—nicotine dependence	0.00046	0.00229	CbGpPWpGaD
Nilotinib—CYP2C8—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000453	0.00226	CbGpPWpGaD
Nilotinib—CA6—Metabolism—CYP2A7—nicotine dependence	0.00045	0.00224	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—WASF2—nicotine dependence	0.000448	0.00223	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—WASF2—nicotine dependence	0.000446	0.00222	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—WASF1—nicotine dependence	0.000429	0.00214	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—WASF1—nicotine dependence	0.000428	0.00213	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—CCAR1—nicotine dependence	0.000423	0.00211	CbGpPWpGaD
Nilotinib—CA7—Metabolism—CYP2A7—nicotine dependence	0.00042	0.00209	CbGpPWpGaD
Nilotinib—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.0004	0.002	CbGpPWpGaD
Nilotinib—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000397	0.00198	CbGpPWpGaD
Nilotinib—CA12—Metabolism—CYP2A7—nicotine dependence	0.000389	0.00194	CbGpPWpGaD
Nilotinib—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000377	0.00188	CbGpPWpGaD
Nilotinib—HCK—Disease—AKR1B10—nicotine dependence	0.000377	0.00188	CbGpPWpGaD
Nilotinib—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.000374	0.00187	CbGpPWpGaD
Nilotinib—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000372	0.00186	CbGpPWpGaD
Nilotinib—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000369	0.00184	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—WASF2—nicotine dependence	0.000357	0.00178	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TAS2R16—nicotine dependence	0.000345	0.00172	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—WASF1—nicotine dependence	0.000342	0.0017	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TAS2R16—nicotine dependence	0.000328	0.00164	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—WASF2—nicotine dependence	0.000322	0.0016	CbGpPWpGaD
Nilotinib—CA4—Metabolism—CYP2A7—nicotine dependence	0.00031	0.00155	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—WASF1—nicotine dependence	0.000308	0.00154	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—WASF2—nicotine dependence	0.000304	0.00152	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—CCAR1—nicotine dependence	0.000302	0.0015	CbGpPWpGaD
Nilotinib—CA2—Metabolism—CYP2A7—nicotine dependence	0.000297	0.00148	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—WASF1—nicotine dependence	0.000292	0.00145	CbGpPWpGaD
Nilotinib—HCK—Immune System—WASF2—nicotine dependence	0.000288	0.00143	CbGpPWpGaD
Nilotinib—CA1—Metabolism—CYP2A7—nicotine dependence	0.000285	0.00142	CbGpPWpGaD
Nilotinib—HCK—Immune System—WASF1—nicotine dependence	0.000276	0.00138	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TAS2R16—nicotine dependence	0.000275	0.00137	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—WASF2—nicotine dependence	0.000274	0.00137	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TAS2R16—nicotine dependence	0.000272	0.00136	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—FGD1—nicotine dependence	0.000271	0.00135	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.00027	0.00135	CbGpPWpGaD
Nilotinib—BRAF—Disease—AKR1B10—nicotine dependence	0.00027	0.00134	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—WASF2—nicotine dependence	0.000268	0.00134	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—WASF2—nicotine dependence	0.000267	0.00133	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—WASF1—nicotine dependence	0.000263	0.00131	CbGpPWpGaD
Nilotinib—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000262	0.00131	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—WASF2—nicotine dependence	0.000261	0.0013	CbGpPWpGaD
Nilotinib—BLK—Immune System—WASF2—nicotine dependence	0.000261	0.0013	CbGpPWpGaD
Nilotinib—FGR—Immune System—WASF2—nicotine dependence	0.00026	0.0013	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—FGD1—nicotine dependence	0.000257	0.00128	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—WASF1—nicotine dependence	0.000257	0.00128	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—WASF1—nicotine dependence	0.000256	0.00128	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—WASF2—nicotine dependence	0.000254	0.00127	CbGpPWpGaD
Nilotinib—CA9—Metabolism—CYP2A7—nicotine dependence	0.000251	0.00125	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—WASF1—nicotine dependence	0.00025	0.00125	CbGpPWpGaD
Nilotinib—BLK—Immune System—WASF1—nicotine dependence	0.00025	0.00125	CbGpPWpGaD
Nilotinib—FGR—Immune System—WASF1—nicotine dependence	0.000249	0.00124	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TAS2R16—nicotine dependence	0.000248	0.00124	CbGpPWpGaD
Nilotinib—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000247	0.00123	CbGpPWpGaD
Nilotinib—KIT—Disease—AKR1B10—nicotine dependence	0.000245	0.00122	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—WASF1—nicotine dependence	0.000244	0.00122	CbGpPWpGaD
Nilotinib—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000243	0.00121	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKR1B10—nicotine dependence	0.000239	0.00119	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TAS2R16—nicotine dependence	0.000235	0.00117	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKR1B10—nicotine dependence	0.000232	0.00116	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKR1B10—nicotine dependence	0.000227	0.00113	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—WASF2—nicotine dependence	0.00022	0.0011	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—FGD1—nicotine dependence	0.000216	0.00108	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—FGD1—nicotine dependence	0.000214	0.00107	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TAS2R16—nicotine dependence	0.000211	0.00105	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—WASF1—nicotine dependence	0.000211	0.00105	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKR1B10—nicotine dependence	0.000209	0.00104	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—WASF2—nicotine dependence	0.000208	0.00104	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TAS2R16—nicotine dependence	0.000207	0.00103	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—WASF1—nicotine dependence	0.000199	0.000993	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TAS2R16—nicotine dependence	0.000196	0.000978	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—FGD1—nicotine dependence	0.000195	0.00097	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKR1B10—nicotine dependence	0.000191	0.00095	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKR1B10—nicotine dependence	0.000189	0.000941	CbGpPWpGaD
Nilotinib—KIT—Immune System—WASF2—nicotine dependence	0.000187	0.000934	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—FGD1—nicotine dependence	0.000184	0.000918	CbGpPWpGaD
Nilotinib—KIT—Immune System—WASF1—nicotine dependence	0.00018	0.000895	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—WASF2—nicotine dependence	0.000177	0.000884	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKR1B10—nicotine dependence	0.000172	0.000857	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—WASF1—nicotine dependence	0.00017	0.000847	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TAS2R16—nicotine dependence	0.00017	0.000846	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—WASF2—nicotine dependence	0.000169	0.00084	CbGpPWpGaD
Nilotinib—LCK—Disease—AKR1B10—nicotine dependence	0.000168	0.000837	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FGD1—nicotine dependence	0.000166	0.000827	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKR1B10—nicotine dependence	0.000163	0.000811	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FGD1—nicotine dependence	0.000162	0.00081	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—WASF1—nicotine dependence	0.000162	0.000806	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—WASF2—nicotine dependence	0.00016	0.000799	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—WASF2—nicotine dependence	0.00016	0.000796	CbGpPWpGaD
Nilotinib—LYN—Immune System—WASF2—nicotine dependence	0.000156	0.00078	CbGpPWpGaD
Nilotinib—ABL1—Immune System—WASF2—nicotine dependence	0.000156	0.000776	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FGD1—nicotine dependence	0.000154	0.000768	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—WASF1—nicotine dependence	0.000154	0.000766	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—WASF1—nicotine dependence	0.000153	0.000763	CbGpPWpGaD
Nilotinib—LYN—Immune System—WASF1—nicotine dependence	0.00015	0.000747	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—CYP2A7—nicotine dependence	0.000149	0.000744	CbGpPWpGaD
Nilotinib—ABL1—Immune System—WASF1—nicotine dependence	0.000149	0.000744	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—WASF2—nicotine dependence	0.000148	0.000739	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKR1B10—nicotine dependence	0.000147	0.000731	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000146	0.000729	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—OPRM1—nicotine dependence	0.000145	0.000725	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKR1B10—nicotine dependence	0.000143	0.000715	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—WASF1—nicotine dependence	0.000142	0.000709	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—OPRM1—nicotine dependence	0.000138	0.00069	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKR1B10—nicotine dependence	0.000136	0.000678	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—WASF2—nicotine dependence	0.000134	0.000669	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FGD1—nicotine dependence	0.000133	0.000664	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—WASF2—nicotine dependence	0.000133	0.000663	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—WASF1—nicotine dependence	0.000129	0.000642	CbGpPWpGaD
Nilotinib—LCK—Immune System—WASF2—nicotine dependence	0.000128	0.000639	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—WASF1—nicotine dependence	0.000128	0.000636	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—CYP2A7—nicotine dependence	0.000127	0.000632	CbGpPWpGaD
Nilotinib—LCK—Immune System—WASF1—nicotine dependence	0.000123	0.000613	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—WASF2—nicotine dependence	0.000121	0.000604	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKR1B10—nicotine dependence	0.000118	0.000586	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—WASF1—nicotine dependence	0.000116	0.000579	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—OPRM1—nicotine dependence	0.000116	0.000578	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—OPRM1—nicotine dependence	0.000115	0.000572	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—WASF2—nicotine dependence	0.000115	0.000571	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—WASF1—nicotine dependence	0.00011	0.000548	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—DRD2—nicotine dependence	0.000105	0.000524	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—OPRM1—nicotine dependence	0.000105	0.000521	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—WASF2—nicotine dependence	0.000103	0.000515	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—WASF2—nicotine dependence	0.000101	0.000504	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—DRD2—nicotine dependence	0.0001	0.000499	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—WASF1—nicotine dependence	9.9e-05	0.000494	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—OPRM1—nicotine dependence	9.89e-05	0.000493	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—WASF1—nicotine dependence	9.69e-05	0.000483	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—WASF2—nicotine dependence	9.58e-05	0.000478	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CYP2A7—nicotine dependence	9.29e-05	0.000463	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—WASF1—nicotine dependence	9.19e-05	0.000458	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—OPRM1—nicotine dependence	8.91e-05	0.000444	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—OPRM1—nicotine dependence	8.73e-05	0.000435	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—DRD2—nicotine dependence	8.38e-05	0.000418	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—DRD2—nicotine dependence	8.3e-05	0.000414	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—WASF2—nicotine dependence	8.29e-05	0.000413	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—OPRM1—nicotine dependence	8.27e-05	0.000412	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—WASF1—nicotine dependence	7.94e-05	0.000396	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CYP2A7—nicotine dependence	7.86e-05	0.000392	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—DRD2—nicotine dependence	7.56e-05	0.000377	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—DRD2—nicotine dependence	7.15e-05	0.000357	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—OPRM1—nicotine dependence	7.15e-05	0.000357	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP2A7—nicotine dependence	6.85e-05	0.000341	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP2A7—nicotine dependence	6.45e-05	0.000322	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—DRD2—nicotine dependence	6.44e-05	0.000321	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP2A7—nicotine dependence	6.4e-05	0.000319	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—DRD2—nicotine dependence	6.31e-05	0.000315	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—DRD2—nicotine dependence	5.98e-05	0.000298	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—DRD2—nicotine dependence	5.17e-05	0.000258	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP2A7—nicotine dependence	4.22e-05	0.00021	CbGpPWpGaD
